Abstract Body

A major concern of dual therapy is the potential lower efficacy in viral reservoirs, especially in the central nervous system (CNS). The aim of this study was to evaluate the maintenance of HIV viral suppression as well as changes in neuronal injury and inflammatory markers in cerebrospinal fluid (CSF) in asymptomatic stable patients switching antiretroviral therapy within a clinical trial.

 

Prospective, single arm study. HIV+ virologically suppressed patients on triple therapy were randomly selected to switch to Lamivudine 300 mg + Dolutegravir 50 mg once daily within the DOLAM Study (EUDRA CT 2015-000274-35). A small group consented to participate in the Neuro-Substudy. All pts were on stable triple therapy and had no history of virological failure to regimens containing 3TC/FTC or INSTI as per inclusion/exclusion criteria. CSF and blood samples were taken at baseline and week 48. Plasma and CSF HIV-1 RNA were assessed by real-time PCR. CSF neurofilament light chain (NFL) as well as inflammatory markers (sTREM2, Neopterine, MCP-1, IL-6) were measured in CSF by sandwich ELISA method.

15 pts had baseline and week 48 plasma and CSF samples. 12 (80%) pts were male. Median (IQR) age was 46 (14) years, baseline and nadir CD4 count 746 (356) and 302 (165) cells/μl respectively. Most patients switched from a NNRTI based regimen (60%) followed by INSTI (26.7%). All subjects maintained plasma viral suppression at baseline, week12, 24, 36 and 48. HIV RNA in CSF was undetectable at baseline and week 48 in all participants (LOD 40 copies/ml). NFL median change from baseline to week 48 was not statistically significant [Median (Min-Max) NFL at baseline: 499 ng/L(268-734); Median (Min-Max) NFL at W48: 457(226-886); p:0.3]. No significant changes were observed in the rest of inflammatory markers in CSF.

Treatment simplification from triple therapy to Dolutegravir+Lamivudine resulted in no changes in viral suppression in plasma and CSF. No evidence of neuronal damage or changes in inflammatory markers were found in CSF after 48 weeks of dual therapy. These data suggest that dual therapy with Dolutegravir+Lamivudine maintains viral control within the CNS reservoir, but larger studies are needed.